CNS Disorders cause 35% of all diseases in Europe and the total associated annual cost was estimated to € 386 billion.

All diseases targeted by Advicenne Pharma have strong unmet medical needs.

There are about 4 to 5 thousand rare diseases in the world for which there is no efficient treatment.

An orphan drug is a drug treating relatively rare and a severe disease with no current alternative treatment. Since Big Pharma companies are generally not interested in these “niche” markets; Regulatory Authorities as well as Governments have offered strong incentives to companies willing to develop new drugs in these fields.

Orphan drug designations allow, among other advantages, ten years exclusivity in Europe, seven years exclusivity in USA, financial help and tax reduction to help fund clinical development, and less time and effort in getting marketing authorisation and registration.

Advicenne Pharma aims to launch on the market, new therapeutic solutions for a certain number of Orphan Diseases.